WallStSmart

ADMA Biologics Inc (ADMA)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

ADMA Biologics Inc generates 68615% more annual revenue ($509.86M vs $742,000). ADMA leads profitability with a 32.4% profit margin vs 0.0%. ADMA earns a higher WallStSmart Score of 49/100 (D+).

ADMA

Hold

49

out of 100

Grade: D+

Growth: 6.7Profit: 8.0Value: 6.0Quality: 8.0
Piotroski: 4/9Altman Z: 4.17

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADMA5 strengths · Avg: 9.2/10
Return on EquityProfitability
42.4%10/10

Every $100 of equity generates 42 in profit

Profit MarginProfitability
32.4%10/10

Keeps 32 of every $100 in revenue as profit

Altman Z-ScoreHealth
4.1710/10

Safe zone — low bankruptcy risk

P/E RatioValuation
12.8x8/10

Attractively priced relative to earnings

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Areas to Watch

ADMA2 concerns · Avg: 1.5/10
EPS GrowthGrowth
-52.8%2/10

Earnings declined 52.8%

Operating MarginProfitability
-123.4%1/10

Operating margin of -123.4%

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ADMA

The strongest argument for ADMA centers on Return on Equity, Profit Margin, Altman Z-Score. Profitability is solid with margins at 32.4% and operating margin at -123.4%. Revenue growth of 15.9% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ADMA

The primary concerns for ADMA are EPS Growth, Operating Margin.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ADMA profiles as a growth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ADMA is growing revenue faster at 15.9% — sustainability is the question.

ADMA generates stronger free cash flow (56M), providing more financial flexibility.

Bottom Line

ADMA scores higher overall (49/100 vs 24/100), backed by strong 32.4% margins and 15.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ADMA Biologics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures and markets plasma-derived biological products specialized for the treatment of immunodeficiencies and infectious diseases in the United States. The company is headquartered in Ramsey, New Jersey.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?